InVivo Therapeutics: 54% of SCI patients improve after participating in INSPIRE study

Spinal Tech

InVivo Therapeutics of Cambridge, Mass., has announced the improving condition of a spinal cord injury-affected patient enrolled in the INSPIRE study of the Neuro Spinal Scaffold.

1.    After being discharged a month ago, the patient's condition has improved from a complete AIS A Spinal cord injury to an incomplete AIS B spinal cord injury.

 

2.    Out of InVivo's 11 INSPIRE patients, this patient now joins five others whose AIS grade has improved after discharge (54 percent).


3.    Two additional patients remain in early follow-up stage, with conversion still possible in the coming months.


4.    Biodegradable Neuro Spinal Scaffold implant allows neural regeneration to take place in wounded/traumatized regions.


5.    InVivo was founded in 2005 with a goal to create and expand groundbreaking technologies and methods of care for SCI.

 

More articles related to the INSPIRE study:
INSPIRE study: University of New Mexico Hospital joins as 30th site
Rhode Island Hospital joins INSPIRE study as 29th clinical site: 5 points
Stryker, Mazor & more: 10 device company key notes

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers